- Home
- / Propanc Biopharma
Propanc Biopharma
Stock Price
$0
2024-10-29
Market Capitalization
$275.2 K
2024-10-29
Propanc Biopharma Summary
Company Summary
- Overview
- Propanc Biopharma is a development-stage healthcare company focused on developing cancer treatments for patients suffering from pancreatic and colorectal cancer. It offers novel proenzyme therapy solutions.
- Type
- Public
- Status
- Active
- Founded
- 2007
- HQ
- Camberwell, AU | view all locations
- Website
- https://www.propanc.com/
- Cybersecurity rating
Table of Contents
Key People
Julian Kenyon, Chief Scientific Officer
Klaus Kutz, Chief Medical Officer
Josef Zelinger, Non-Executive Director
LocationsView all
1 location detected
Camberwell, VIC HQ
Australia
302/6 Butler St
Propanc Biopharma Financials
Summary Financials
- Net income (Q3, 2026)
- ($6.4M)
- Cash (Q3, 2026)
- $443.7K
- EBIT (Q3, 2026)
- ($6.4M)
- Enterprise value
- $118.3K
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026